Foresee Pharmaceuticals is a Taiwan and US-based biopharmaceutical company listed on Taipei Exchange（TPEx：6576）. Foresee's R&D activities consist of two areas, the proprietary stabilized injectable formulation (SIF) targeting specialty markets, and the first-in-class NCE programs targeting rare and severe diseases. CAMCEVI® 42 mg (6-month depot injection formulation), indicated for the treatment of advanced prostate cancer, was the first commercial product developed from Foresee's SIF platform. CAMCEVI® 42 mg has been approved in the US, EU, Canada, and was launched in the US in April 2022. Additionally, US and EU regulatory submissions are under preparation for CAMCEVI® 21 mg. FP-025, a first-in-class oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, is currently in a Phase 2 proof-of-concept study in allergic asthma. FP-045, a first-in-class oral ALDH2 activator, for which a Phase 1b/2 Fanconi Anemia study is currently being initiated.